Precision epidemiology informing the drug development lifecycle.

Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.

Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.

Research and DevelopmentDetermining disease prevalence to establish development priorities.
Clinical TrialsDefining the most relevant patient groups to include in trials.
Market AccessGenerating disease burden studies to support HEOR teams with reimbursement and market access.
Market ExpansionDemonstrating the impact of new therapies on public health, and quantifying the impact of interventions.
Patient AdvocacyHighlighting unmet needs, and helping patient education campaigns raise awareness.

From molecule to market, our solutions can help.


Helping you at every stage

From informing early-stage R&D decisions through to market access and launch, view our solutions to find out how our data-driven epidemiology can support your product development, strategic planning and portfolio management.

Why Us?

Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.

Why Us?

How do we do it?

We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.


Whats our Track Record?

We’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.

Track Record


Our experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.

About Us

HealthLumen Blog

Investing in prevention for men’s health: Increasing NHS Health Check attendance could save the NHS billions

HealthLumen was recently commissioned by Movember, one of the leading charities changing the face of men’s health, to quantify the economic impact of men’s poor health for their ‘Real Face of Men’s Health’ 2024 UK Report.  The study found that in 2023 the five diseases that cause the largest number of years of life lost […]


NEWS: New genetic database analysis study reveals FNAIT risk across racially and ethnically diverse populations

HealthLumen has recently conducted a genetic database analysis study in partnership with Rallybio, a clinical-stage biotechnology company, focused on understanding the proportions of women at higher risk for Foetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) across a broad population of diverse ancestries. The results demonstrated that the proportion of women at higher risk for FNAIT was […]


Supporting rare disease patient advocacy with epidemiological insights

Awareness of the vast impact of rare diseases, which affect approximately 300 million people globally (1), has significantly increased over the years, leading to increased funding and investment in rare disease research and therapy development.   Although more than half of the novel drug approvals by the FDA’s Center for Drug Evaluation and Research last […]


CKD epidemic: Global prevalence and economic burden set to surge by 2027 unless action is taken, Inside CKD studies reveal

In partnership with AstraZeneca, HealthLumen has recently published two publications that project the clinical (1) and economic (2) burden of Chronic Kidney Disease (CKD) and Kidney Replacement Therapy (KRT) into the future, as part of the “Inside CKD” programme, which contributes to the major strategic initiative at AstraZeneca dedicated to driving better patient outcomes. From […]